glp-1 pdb RCSB Human GLP-1 receptor transmembrane domain

In the LEADER trial, over 9,340 patients with type 2 diabetes and high cardiovascular disease risk underwent randomization to liraglutide or placebo and were followed for a median of 3.8 years resulting in a 13% risk reduction in a combined endpoint of death from cardiovascular cause, nonfatal myocardial infarction, or nonfatal stroke [46]

While nausea, diarrhea, and constipation are well-documented reactions, some patients report noticing mucus in stool during treatment

The promo plan saves $85 if and only if you clear the balance before the promotion ends

I ran the analysis and built the chart with help from hashtag #ChatGPT5

It supports keeping patients on therapies that benefit their health whenever it is safe to do so.

Subscribe to our latest research Get the latest insights delivered to your inbox